within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD10_MetforminAndSaxagliptin;

model MetforminAndSaxagliptin
  extends Pharmacolibrary.Drugs.ATC.A.A10BD10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Combination of metformin, a biguanide antihyperglycemic agent, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Used for the treatment of type 2 diabetes mellitus to improve glycemic control, as an adjunct to diet and exercise. Approved for use in multiple regions.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults based on published data for individual components; no direct published pharmacokinetics of combination found.</p><h4>References</h4><ol><li><p>Patel, CG, et al., &amp; Boulton, DW (2011). Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. <i>Diabetes, obesity &amp; metabolism</i> 13(7) 604–614. DOI:<a href=\"https://doi.org/10.1111/j.1463-1326.2011.01381.x\">10.1111/j.1463-1326.2011.01381.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21332626/\">https://pubmed.ncbi.nlm.nih.gov/21332626</a></p></li><li><p>Boulton, DW, et al., &amp; LaCreta, FP (2011). Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. <i>Clinical drug investigation</i> 31(9) 619–630. DOI:<a href=\"https://doi.org/10.2165/11590290-000000000-00000\">10.2165/11590290-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21819160/\">https://pubmed.ncbi.nlm.nih.gov/21819160</a></p></li><li><p>Upreti, VV, et al., &amp; Lacreta, FP (2013). Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects. <i>Clinical drug investigation</i> 33(5) 365–374. DOI:<a href=\"https://doi.org/10.1007/s40261-013-0075-z\">10.1007/s40261-013-0075-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23549864/\">https://pubmed.ncbi.nlm.nih.gov/23549864</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MetforminAndSaxagliptin;
